Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 14;21(1):296.
doi: 10.1186/s12906-021-03469-x.

Tetrandrine alleviates podocyte injury via calcium-dependent calpain-1 signaling blockade

Affiliations

Tetrandrine alleviates podocyte injury via calcium-dependent calpain-1 signaling blockade

Yin Ding et al. BMC Complement Med Ther. .

Abstract

Background: Podocytes have become a crucial target for interventions in proteinuric kidney diseases. Many studies have reported that overexpression of transient receptor potential cation channel protein 6 (TRPC6) in podocyte injury upregulates intracellular Ca2+ influx and stimulates Ca2+-dependent protease calpain-1 signaling. The traditional Chinese drug, tetrandrine, a nonselective Ca2+ channel blocker, has long been used to treat chronic kidney disease. This research aimed to explore the possible mechanisms underlying the anti-proteinuric properties of tetrandrine.

Methods: We investigated the involvement of tetrandrine in Ca2+ dependent calpain-1 signaling in mouse podocytes and adriamycin-induced nephropathy rats. Cyclosporine A (CsA) and U73122 were used as positive controls. Cell viability, cytotoxicity, Ca2+ concentration, calpain activity, and mRNA and protein expression levels of calpain-1 signaling pathways were examined. The clinical and pathological changes were measured.

Results: Tetrandrine decreased intracellular Ca2+ influx in cultured TRPC6-overexpressing podocytes. In both in vitro and in vivo studies, the administration of tetrandrine downregulated calpain activity and the expression of calpain-1 and restored the expression of downstream Talin-1 and nephrin. Compared to CsA, tetrandrine treatment exhibited superior inhibitory effects on calpain activity and calpain-1 expression.

Conclusions: Tetrandrine has therapeutic potential in podocyte damage by blocking Ca2+-dependent activation of the calpain-1 signaling pathway. Tetrandrine reduced proteinuria, improved renal function, and alleviate renal pathological damage.

Keywords: Calpain-1; Podocyte injury; Tetrandrine; Transient receptor potential cation channel protein 6.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there exist no conflicts of interest.

Figures

Fig. 1
Fig. 1
Optimization of drug concentrations. MPC5 podocyte viability under treatment with different concentrations of tetrandrine (a) and CsA (b) detected by CCK8 assay. c The LDH cytotoxicity assay in MPC5 podocytes treated with tetrandrine, CsA and U73122. * P<0.05. NC: normal control. Lv-NC: blank lentivirus. OverTRP: TRPC6-overexpressing
Fig. 2
Fig. 2
Construction of TRPC6 overexpressing cell model, and detection of Ca2+ influx among groups. The mRNA and protein levels of TRPC6 were determined by qRT-PCR (a) and western blotting (b), respectively. The intracellular Ca2+ influx was determined using Fluo-3 AM under confocal microscope (c) and semiquantitative analysis (d). Different letters represent statistically different values (P < 0.05), whereas the same letters indicate no significant difference
Fig. 3
Fig. 3
Tetrandrine decreased Ca2+-dependent calpain-1 signaling in cultured podocytes. a Calpain and b calcineurin activity were measured. c Typical bands showing the protein levels of TRPC6, calpain-1, calcineurin, Talin-1 and nephrin, normalized to GAPDH. Detection of mRNA d-g and protein levels h-k of calpain-1, calcineurin, Talin-1 and nephrin, respectively. CsA and U73122 were used as positive controls. Different letters represent statistically different values (P < 0.05), whereas the same letters indicate no significant difference
Fig. 4
Fig. 4
Tetrandrine-mediated inhibition of Ca2+/calpain-1 signaling in adriamycin-induced nephropathy rats. TRPC6 overexpressing rat model was established (a, b). c Calpain and (d) calcineurin activity was measured. e Typical bands showing the protein levels of TRPC6, calpain-1, calcineurin, Talin-1 and nephrin, normalized to GAPDH. The mRNA (f-i) and protein expressions (j-m) of calpain-1, Talin-1, calcineurin and nephrin, respectively. CsA was used as the positive control. Different letters represent statistically different values (P < 0.05), whereas the same letters indicate no significant difference
Fig. 5
Fig. 5
Protective effects of drugs on renal function in adriamycin-induced nephropathy rats. 24 h-proteinuria (a), plasma albumin (b), serum creatinine (c), and blood urea nitrogen (d) were measured and compared. Different letters represent statistically different values (P < 0.05), whereas the same letters indicate no significant difference
Fig. 6
Fig. 6
Morphological characteristics of kidney in rats. Typical morphological characteristics of glomerulus under light microscopy (HE staining, magnification: 400×) and electron microscopic evaluation of podocyte structure among different groups of rats (magnification: 20000×)

References

    1. Garg P. A review of podocyte biology. Am J Nephrol. 2018;47(Suppl 1):3–13. doi: 10.1159/000481633. - DOI - PubMed
    1. Khalilpourfarshbafi M, Hajiaghaalipour F, Selvarajan KK, et al. Mesenchymal stem cell-based therapies against podocyte damage in diabetic nephropathy. Tissue Eng Regen Med. 2017;14:201–210. doi: 10.1007/s13770-017-0026-5. - DOI - PMC - PubMed
    1. Nagata M. Podocyte injury and its consequences. Kidney Int. 2016;89:1221–1230. doi: 10.1016/j.kint.2016.01.012. - DOI - PubMed
    1. Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003;83:253–307. doi: 10.1152/physrev.00020.2002. - DOI - PubMed
    1. Riehle M, Büscher AK, Gohlke B-O, et al. TRPC6 G757D loss-of-function mutation associates with FSGS. J Am Soc Nephrol. 2016;27:2771–2783. doi: 10.1681/ASN.2015030318. - DOI - PMC - PubMed